News | December 01, 2024
Dr. Reddy's launches Toripalimab in India
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Subscribe To Our Newsletter & Stay Updated
